Skip to main content

Restlessness

body effect

valenceadversefrequencycommontemporalacute

AI-inferred — this entry was drafted by AI and has not yet been verified against primary sources. A sourced revision is planned.

Restlessness is an inability to remain still, characterized by an urge to move or shift position that brings no lasting relief.

As a drug effect it is acute and dose-proportional, easing as the substance wears off; this distinguishes it from restlessness linked to chronic anxiety or movement disorders. It ranges from mild fidgety agitation to an overwhelming compulsion to pace.

Restlessness is among the more commonly reported adverse body effects across psychoactive substances. It is most commonly induced at moderate to high doses under psychedelics such as LSD and psilocybin mushrooms, and under stimulants such as amphetamine and 2-FMA. It also appears under dissociatives such as 3-MeO-PCE and 3-HO-PCP, and under deliriants such as diphenhydramine and datura.

phenomenology

Restlessness is felt as a persistent motor pressure: an inner urge to move that does not resolve when movement is made. It commonly comes with tightness in the legs and arms, an inability to hold any position, and a buzzing sensation in the muscles that sitting still only worsens.

Attending to it amplifies it — the more a person tries to settle, the more insistent the urge becomes. At higher doses, particularly under stimulants and dissociatives, it can escalate into compulsive pacing or repetitive motion.

mechanism

Restlessness arises through different pathways depending on the drug class:

  • Psychedelics — heightened serotonergic activity amplifies proprioceptive signaling, making sustained stillness difficult to tolerate.
  • Stimulants — dopaminergic and noradrenergic arousal lowers the threshold for physical inactivity, producing motor agitation.
  • Dissociatives — NMDA receptor blockade disrupts normal body-position signaling, generating an unsettled somatic state.
  • Deliriants — anticholinergic activity produces akathisia-like motor restlessness, particularly at higher doses.

How much each pathway contributes in a given case is not fully understood.

variability

Who experiences it, and how strongly, varies widely. Higher doses raise both likelihood and intensity across all contributing classes. It is more pronounced under stimulants and psychedelics — especially in unfamiliar settings or under pre-existing physical tension — and in those with prior sensitivity to stimulation or a history of movement-related agitation.

Expecting it tends to heighten vigilance toward early signals, making it worse. A calm setting and a relaxed body going in tend to reduce its intensity.

practices

experience reports

No experience reports yet. Be the first to contribute.

First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.

AI-generated · claude-sonnet-4-6 · reviewed

Harm-reduction reference — not medical advice.

Last updated May 25, 2026Report an issue